61 days in nonimmune responders; = 0
61 days in nonimmune responders; = 0.0002), when using a KRAS vaccine adjusted to the patients mutation. Carcinoembryonic antigen is definitely another vaccination target of interest tested in PDAC. [26] Open in a separate windowpane CTLA-4, cytotoxic T lymphocyte-associated protein 4; PDAC, pancreatic ductal adenocarcinoma; PR, partial remission; SD, stable disease; PD-L1, programmed cell death…